288 research outputs found
Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients - Results from an experimental study
The influence of antipsychotic treatment on the neuropsychological and psychomotor performance of schizophrenic patients is still a subject of investigation. The present study was designed to evaluate the effects of atypical neuroleptics in comparison with a conventional dopamine antagonist neuroleptic (haloperidol) on several dimensions of psychomotor performance (visual perception, attention, reaction time, and sensorimotor performance) considered to be of relevance in evaluating driving fitness. Psychomotor performance was assessed by means of the ART 90, a computerized Act and React Test which is generally used in diagnosis of psychomotor performance. The 49 participating patients were examined at discharge following psychopathological stabilisation; 20 received haloperidol, 29 received an atypical neuroleptic. Our findings demonstrate a remarkably reduced psychomotor performance in the haloperidol-treated group of schizophrenic patients compared with patients treated with atypical neuroleptics. Only 1 (5%) subject passed all subtests without major failures and could be regarded as competent to drive. Among patients with atypical neuroleptics, 7 patients (24%) passed all test parameters without major failures. Copyright (C) 2003 S. Karger AG, Basel
Streptokokken B : Reduktion der intrapartalen Antibiotikaprophylaxe bei Streptokokken B positiven Frauen in der Schweiz
Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients - Results from an experimental study
The influence of antipsychotic treatment on the neuropsychological and psychomotor performance of schizophrenic patients is still a subject of investigation. The present study was designed to evaluate the effects of atypical neuroleptics in comparison with a conventional dopamine antagonist neuroleptic (haloperidol) on several dimensions of psychomotor performance (visual perception, attention, reaction time, and sensorimotor performance) considered to be of relevance in evaluating driving fitness. Psychomotor performance was assessed by means of the ART 90, a computerized Act and React Test which is generally used in diagnosis of psychomotor performance. The 49 participating patients were examined at discharge following psychopathological stabilisation; 20 received haloperidol, 29 received an atypical neuroleptic. Our findings demonstrate a remarkably reduced psychomotor performance in the haloperidol-treated group of schizophrenic patients compared with patients treated with atypical neuroleptics. Only 1 (5%) subject passed all subtests without major failures and could be regarded as competent to drive. Among patients with atypical neuroleptics, 7 patients (24%) passed all test parameters without major failures. Copyright (C) 2003 S. Karger AG, Basel
Die schicksalsreiche Geschichte des Bildes "Die Schöne Maria" von Albrecht Altdorfer in der Stiftskirche St. Johann in Regensburg
Synaptogenic gene therapy with FGF22 improves circuit plasticity and functional recovery following spinal cord injury
Functional recovery following incomplete spinal cord injury (SCI) depends on the rewiring of motor circuits during which supraspinal connections form new contacts onto spinal relay neurons. We have recently identified a critical role of the presynaptic organizer FGF22 for the formation of new synapses in the remodeling spinal cord. Here, we now explore whether and how targeted overexpression of FGF22 can be used to mitigate the severe functional consequences of SCI. By targeting FGF22 expression to either long propriospinal neurons, excitatory interneurons, or a broader population of interneurons, we establish that FGF22 can enhance neuronal rewiring both in a circuitâspecific and comprehensive way. We can further demonstrate that the latter approach can restore functional recovery when applied either on the day of the lesion or within 24âh. Our study thus establishes viral gene transfer of FGF22 as a new synaptogenic treatment for SCI and defines a critical therapeutic window for its application
Magnetic relaxation measurements of exchange biased (Pt/Co) multilayers with perpendicular anisotropy
Magnetic relaxation measurements were carried out by magneto-optical Kerr
effect on exchange biased (Pt/Co)5/Pt/FeMn multilayers with perpendicular
anisotropy. In these films the coercivity and the exchange bias field vary with
Pt spacer thickness, and have a maximum for 0.2 nm. Hysteresis loops do not
reveal important differences between the reversal for ascending and descending
fields. Relaxation measurements were fitted using Fatuzzo's model, which
assumes that reversal occurs by domain nucleation and domain wall propagation.
For 2 nm thick Pt spacer (no exchange bias) the reversal is dominated by domain
wall propagation starting from a few nucleation centers. For 0.2 nm Pt spacer
(maximum exchange bias) the reversal is strongly dominated by nucleation, and
no differences between the behaviour of the ascending and descending branches
can be observed. For 0.4 nm Pt spacer (weaker exchange bias) the nucleation
density becomes less important, and the measurements reveal a much stronger
density of nucleation centers in the descending branch.Comment: Europhysical Journal B, in print DOI: 10.1140/epjb/e2005-00053-
Synaptogenic gene therapy with FGF22 improves circuit plasticity and functional recovery following spinal cord injury
Functional recovery following incomplete spinal cord injury (SCI) depends on the rewiring of motor circuits during which supraspinal connections form new contacts onto spinal relay neurons. We have recently identified a critical role of the presynaptic organizer FGF22 for the formation of new synapses in the remodeling spinal cord. Here, we now explore whether and how targeted overexpression of FGF22 can be used to mitigate the severe functional consequences of SCI. By targeting FGF22 expression to either long propriospinal neurons, excitatory interneurons, or a broader population of interneurons, we establish that FGF22 can enhance neuronal rewiring both in a circuit-specific and comprehensive way. We can further demonstrate that the latter approach can restore functional recovery when applied either on the day of the lesion or within 24 h. Our study thus establishes viral gene transfer of FGF22 as a new synaptogenic treatment for SCI and defines a critical therapeutic window for its application
Polygenic risk for Alzheimerâs disease is associated with neuroaxonal damage before onset of clinical symptoms
Orbital Complexity in Intrinsic Magnetic Topological Insulators MnBi<sub>4</sub>Te<sub>7</sub> and MnBi<sub>6</sub>Te<sub>10</sub>
- âŠ